LNAI
Lunai Bioworks Inc.
NASDAQ · Healthcare · Biotechnology · US
$2.39
+1.70%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 20.9K | — | — | — | — |
| Cost of Revenue | 96.5K | 129.1K | — | — | — |
| Gross Profit | (75.5K) | (129.1K) | — | — | — |
| Operating Expenses | |||||
| R&D Expense | 166.5K | 537.4K | 2.7M | 4.2M | 8.4M |
| SG&A Expense | 9.6M | 17.9M | 24.6M | 15.3M | 14.3M |
| General & Admin Expense | 6.4M | 17.9M | 24.6M | 15.3M | 14.3M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | — | — | 54.4M | 19.1M | 93.4M |
| Total Operating Expenses | 9.8M | 18.4M | 81.6M | 38.6M | 116.1M |
| Cost and Expenses | 9.9M | 18.5M | 81.6M | 38.6M | 116.1M |
| Operating Income (EBIT) | (9.8M) | (18.5M) | (81.6M) | (38.6M) | (116.1M) |
| Non-Operating | |||||
| Interest Income | 6.9K | 116.3K | — | — | 122.0K |
| Interest Expense | 606.3K | 725.7K | 2.4M | 707.0K | 372.8K |
| Net Interest Income | (599.3K) | (609.3K) | (2.4M) | (707.0K) | (250.8K) |
| Other Non-Op Income/Expense | (118.4M) | (159.5M) | (6.8M) | (1.1M) | 2.6M |
| Non-Operating Income (excl Interest) | 117.8M | 158.7M | 4.4M | 420.2K | (3.0M) |
| EBT (Pre-Tax Income) | (128.3M) | (178.0M) | (88.4M) | (39.7M) | (113.4M) |
| Income Tax Expense | — | — | — | — | 34.00 |
| Bottom Line | |||||
| Net Income | (128.3M) | (178.0M) | (88.4M) | (39.7M) | (113.4M) |
| Earnings from Cont. Ops | (128.3M) | (178.0M) | (88.4M) | (39.7M) | (113.4M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (128.3M) | (178.0M) | (88.4M) | (39.7M) | (113.4M) |
| Per Share | |||||
| Basic EPS | ($61.25) | ($86.24) | ($72.80) | ($56.80) | ($172.80) |
| Diluted EPS | ($61.25) | ($86.24) | ($72.80) | ($56.80) | ($172.80) |
| Revenue Per Share | $0.01 | $0.00 | $0.00 | $0.00 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 3.1M | 2.1M | 1.2M | 703317 | 656600 |
| Diluted Shares Outstanding | 3.1M | 2.1M | 1.2M | 703317 | 656600 |
| Profitability Metrics | |||||
| EBITDA | (127.6M) | (177.2M) | (85.9M) | (38.9M) | (112.9M) |
| D&A | 96.5K | 129.1K | 121.9K | 113.5K | 123.6K |
| EBIT | (127.7M) | (177.3M) | (86.0M) | (39.0M) | (113.1M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026